CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Tabletop particle accelerator could transform medicine and materials science 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Lab-grown meat: you may find it icky, but it could drive forward medical research 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older with hemophilia A or B, with or without inhibitors, Qfitlia offers a major shift in treatment convenience with its bimonthly subcutaneous (under-the-skin) dosing—compared to weekly or even daily injections currently on the market.
This first-in-class therapy works by reducing antithrombin, a protein that delays blood clotting, and significantly lowers the risk of bleeding episodes. In clinical trials, Qfitlia showed a 90% reduction in annualized bleeding rates compared to traditional on-demand treatments, highlighting its effectiveness in preventing spontaneous and injury-related bleeding.
Set for U.S. launch in April, Qfitlia will carry an annual list price of $642,000 for most patients, according to Brian Foard, Sanofi’s head of specialty care. U.S.-listed shares of Sanofi rose 1.7% following the approval announcement.
With approximately 33,000 males in the United States living with hemophilia, according to the CDC, Qfitlia provides a much-needed quality-of-life improvement. Unlike traditional factor replacement therapies, or newer gene therapies like CSL’s Hemgenix and BioMarin’s Roctavian, Qfitlia introduces a convenient and effective middle ground.
Experts like Margaret Ragni, professor at the University of Pittsburgh, emphasize the benefit: “Taking a drug every other month is a remarkable simplification for patients.”
As the hemophilia treatment landscape evolves, Sanofi’s Qfitlia could mark a new standard in care by balancing convenience, innovation, and efficacy for patients with this rare and chronic blood disorder.
